ABVC - ABVC BioPharma vs. Regencell: Similarities end in valuation

ABVC BioPharma (ABVC -23.0%), a clinical-stage biopharma company based in Fremont, California, once surged over 900% in the pre-market to end the week among the top three micro-cap stocks in the healthcare sector. While online chatter fueled its meteoric rise, Seeking Alpha users pounced on the stock, making it the hottest new healthcare stock with 59 new additions for every removal. Formerly called American BriVision, ABVC (NASDAQ:ABVC) has six drugs and a medical device in its portfolio, including ABV-1504 and ABV-1505. Two clinical-stage assets are targeted at major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD), respectively. PDC-1421, an extract of Polygala tenuifolia (a plant grown mainly in China), is the active ingredient of both compounds, which are currently undergoing Phase 2 studies. Meanwhile, Hong Kong-based Regencell Bioscience Holdings (RGC +9.2%) focuses on advancing traditional Chinese medicines for the treatment of neurocognitive disorders such as ADHD and autism spectrum disorder (ASD).

For further details see:

ABVC BioPharma vs. Regencell: Similarities end in valuation